<code id='AB55392B35'></code><style id='AB55392B35'></style>
    • <acronym id='AB55392B35'></acronym>
      <center id='AB55392B35'><center id='AB55392B35'><tfoot id='AB55392B35'></tfoot></center><abbr id='AB55392B35'><dir id='AB55392B35'><tfoot id='AB55392B35'></tfoot><noframes id='AB55392B35'>

    • <optgroup id='AB55392B35'><strike id='AB55392B35'><sup id='AB55392B35'></sup></strike><code id='AB55392B35'></code></optgroup>
        1. <b id='AB55392B35'><label id='AB55392B35'><select id='AB55392B35'><dt id='AB55392B35'><span id='AB55392B35'></span></dt></select></label></b><u id='AB55392B35'></u>
          <i id='AB55392B35'><strike id='AB55392B35'><tt id='AB55392B35'><pre id='AB55392B35'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:explore    Page View:6
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In